The good, the bad, and the modified: CYLD’s post-translational tale

The deubiquitinating enzyme CYLD hydrolyzes Lys63-and Met1-linked ubiquitin chains, playing a crucial role in regulating various cellular processes such as immune cell development, innate and adaptive immunity, spermatogenesis, ciliogenesis, and cell survival. CYLD also functions as a tumor suppressor and is mutated in familial cylindromatosis. This pleiotropic function implies tight regulatory mechanisms. In this review, we summarize the current knowledge on CYLD’s molecular characteristics, subcellular location, and binding partners, with a focus on its involvement in life-and-death decisions. In addition, we discuss how post-translational modifications, including phosphorylation, ubiquitination, and proteolysis, shape CYLD’s function, unveiling the potential for therapeutic intervention. Finally, we highlight the remaining challenges that need to be overcome to deepen our understanding of this crucial enzyme.

Authors

Institutions

Publication Details

Journal
Frontiers in Cell Death
Published
2025-04-09
DOI
https://doi.org/10.3389/fceld.2025.1583221
Citations
3
Primary Topic
Ubiquitin and proteasome pathways
Type
article
Field-Weighted Citation Impact
2.42

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The good, the bad, and the modified: CYLD’s post-translational tale

Nicolas Bidère, Tiphaine Douanne, Yanis M. Macé
3 citations
Frontiers in Cell Death
Ubiquitin and proteasome pathways
2.42
article

The good, the bad, and the modified: CYLD’s post-translational tale

Nicolas Bidère, Tiphaine Douanne, Yanis M. Macé
article en
3 citations

Abstract

The deubiquitinating enzyme CYLD hydrolyzes Lys63-and Met1-linked ubiquitin chains, playing a crucial role in regulating various cellular processes such as immune cell development, innate and adaptive immunity, spermatogenesis, ciliogenesis, and cell survival. CYLD also functions as a tumor suppressor and is mutated in familial cylindromatosis. This pleiotropic function implies tight regulatory mechanisms. In this review, we summarize the current knowledge on CYLD’s molecular characteristics, subcellular location, and binding partners, with a focus on its involvement in life-and-death decisions. In addition, we discuss how post-translational modifications, including phosphorylation, ubiquitination, and proteolysis, shape CYLD’s function, unveiling the potential for therapeutic intervention. Finally, we highlight the remaining challenges that need to be overcome to deepen our understanding of this crucial enzyme.

Frontiers in Cell DeathVol. 4
Centre National de la Recherche Scientifique (FR), Inserm (FR), Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers (FR), La Ligue Contre le Cancer (FR), Nantes Université (FR)
Institut National de la Santé et de la Recherche Médicale, Fondation ARC pour la Recherche sur le Cancer, Institut National Du Cancer, Fondation Bettencourt Schueller, Direction Générale de l’offre de Soins
Openalex Percentile: Top 12%
Ubiquitin and proteasome pathways
2.42
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.